CanSino, WuXi, Fujifilm and more—FiercePharmaAsia by Angus Liu Friday, May 22, 2020 CanSino licenses an mRNA coronavirus vaccine. WuXi Biologics set to build $60 million U.S. facility. A Fujifilm drug reportedly fails in COVID-19.
Gilead, India, Samsung Bioepis and more—FiercePharmaAsia by Angus Liu Friday, April 24, 2020 Did Gilead fail a Chinese COVID-19 study? Production at a Indian drug manufacturing hub slows down. Samsung launches Hereptin biosim in the U.S.
Samsung execs face jail time over evidence destruction by Angus Liu Monday, December 9, 2019 Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.
Manufacturing News of Note—Boehringer Ingelheim to add 105 jobs Thursday, November 14, 2019 Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.
Amgen-BeiGene, AZ, Alzheimer's and more—FiercePharmaAsia by Angus Liu Friday, November 8, 2019 Amgen pays $2.7 billion for a 20.5% stake in BeiGene. AstraZeneca tightens its ties to China as China approves a controversial Alzheimer's drug.
Biogen expands biosim deal to cover Lucentis, Eylea and China by Angus Liu Thursday, November 7, 2019 Biogen is putting down $100 million upfront for copycats to Roche's Lucentis, Regeneron's Eylea and new rights for anti-TNF drugs in China.
Sandoz-Aurobindo, Zolgensma, AZ and more—FiercePharmaAsia by Angus Liu Friday, October 25, 2019 FTC review delays Sandoz-Aurobindo generics deal. Manufacturing questions push back Zolgensma decision in Japan. AZ expects mid-teens China growth.
Samsung Bioepis, Celltrion, GenScript and more—FiercePharmaAsia by Angus Liu Friday, July 26, 2019 Samsung Bioepis wins FDA nod for a Humira biosim; Celltrion forms Chinese biosim joint venture; GenScript debuts a clinical biologics plant.
Hansoh-Hengrui, Samsung and more—FiercePharmaAsia by Angus Liu Friday, June 14, 2019 Hansoh and Hengrui chiefs together make one of biopharma's richest families; prosecutors grill top Samsung exec; FDA cites another Aurobindo plant.
FDA boosts Roche breast cancer hopes with new Kadcyla approval by Kyle Blankenship Monday, May 6, 2019 With a new FDA nod in postsurgery patients—and Herceptin biosimilars looming—Roche's Kadcyla has more space to run.
